P W Kantoff

Summary

Affiliation: Harvard University
Country: USA

Publications

  1. ncbi request reprint New developments in the management of prostate cancer
    Philip W Kantoff
    The Lank Center for Genitourinary Oncology and Solid Tumor Oncology at Dana Farber Cancer Institute Brigham and Women s Hospital, Boston, Massachusetts 02115, USA
    J Natl Compr Canc Netw 11:653-7. 2013
  2. doi request reprint Integration of immunotherapy into the management of advanced prostate cancer
    Philip Kantoff
    Lank Center for Genitourinary Oncology, Division of Solid Tumor Oncology, Department of Medical Oncology, Dana Farber Cancer Institute, Harvard Medical School, Boston, MA 02215, USA
    Urol Oncol 30:S41-7. 2012
  3. pmc Molecular sampling of prostate cancer: a dilemma for predicting disease progression
    Andrea Sboner
    Department of Pathology and Laboratory Medicine, Weill Cornell Medical Center, New York, NY, USA
    BMC Med Genomics 3:8. 2010
  4. ncbi request reprint Sipuleucel-T immunotherapy for castration-resistant prostate cancer
    Philip W Kantoff
    Dana Farber Cancer Institute, Harvard Medical School, Boston, MA 02115, USA
    N Engl J Med 363:411-22. 2010
  5. ncbi request reprint Prognostic significance of reverse transcriptase polymerase chain reaction for prostate-specific antigen in men with hormone-refractory prostate cancer
    P W Kantoff
    Lank Center for Genitourinary Oncology, Department of Adult Oncology, Dana Farber Cancer Institute, Boston, MA, USA
    J Clin Oncol 19:3025-8. 2001
  6. ncbi request reprint Finasteride and flutamide therapy in patients with advanced prostate cancer: response to subsequent castration and long-term follow-up
    William K Oh
    Lank Center for Genitourinary Oncology, Department of Medical Oncology, Dana Farber Cancer Institute and Harvard Medical School, Boston, Massachusetts 02115, USA
    Urology 62:99-104. 2003
  7. doi request reprint Interval to testosterone recovery after hormonal therapy for prostate cancer and risk of death
    Anthony V D'Amico
    Department of Radiation Oncology, Brigham and Women s Hospital and Dana Farber Cancer Institute, Boston, MA 02215, USA
    Int J Radiat Oncol Biol Phys 75:10-5. 2009
  8. pmc Estrogen-dependent signaling in a molecularly distinct subclass of aggressive prostate cancer
    Sunita R Setlur
    Department of Pathology, Brigham and Women s Hospital, Boston, MA, USA
    J Natl Cancer Inst 100:815-25. 2008
  9. doi request reprint Evaluating the combined effect of comorbidity and prostate-specific antigen kinetics on the risk of death in men after prostate-specific antigen recurrence
    Jennifer Y Wo
    Harvard Radiation Oncology Program, Harvard Medical School, Boston, MA, USA
    J Clin Oncol 27:6000-5. 2009
  10. pmc Phase II study of sunitinib in men with advanced prostate cancer
    M Dror Michaelson
    Division of Hematology Oncology, Massachusetts General Hospital, Boston, MA 02114, USA
    Ann Oncol 20:913-20. 2009

Collaborators

Detail Information

Publications109 found, 100 shown here

  1. ncbi request reprint New developments in the management of prostate cancer
    Philip W Kantoff
    The Lank Center for Genitourinary Oncology and Solid Tumor Oncology at Dana Farber Cancer Institute Brigham and Women s Hospital, Boston, Massachusetts 02115, USA
    J Natl Compr Canc Netw 11:653-7. 2013
    ..He explained how better treatment decisions will result from individualized estimation of threat-to-life posed by prostate cancer, chance of cure by treatment, and treatment risks...
  2. doi request reprint Integration of immunotherapy into the management of advanced prostate cancer
    Philip Kantoff
    Lank Center for Genitourinary Oncology, Division of Solid Tumor Oncology, Department of Medical Oncology, Dana Farber Cancer Institute, Harvard Medical School, Boston, MA 02215, USA
    Urol Oncol 30:S41-7. 2012
    ....
  3. pmc Molecular sampling of prostate cancer: a dilemma for predicting disease progression
    Andrea Sboner
    Department of Pathology and Laboratory Medicine, Weill Cornell Medical Center, New York, NY, USA
    BMC Med Genomics 3:8. 2010
    ..Hence, we sought to develop a molecular panel for prostate cancer progression by reasoning that molecular profiles might further improve current clinical models...
  4. ncbi request reprint Sipuleucel-T immunotherapy for castration-resistant prostate cancer
    Philip W Kantoff
    Dana Farber Cancer Institute, Harvard Medical School, Boston, MA 02115, USA
    N Engl J Med 363:411-22. 2010
    ..Sipuleucel-T, an autologous active cellular immunotherapy, has shown evidence of efficacy in reducing the risk of death among men with metastatic castration-resistant prostate cancer...
  5. ncbi request reprint Prognostic significance of reverse transcriptase polymerase chain reaction for prostate-specific antigen in men with hormone-refractory prostate cancer
    P W Kantoff
    Lank Center for Genitourinary Oncology, Department of Adult Oncology, Dana Farber Cancer Institute, Boston, MA, USA
    J Clin Oncol 19:3025-8. 2001
    ..To evaluate the prognostic significance of reverse transcriptase polymerase chain reaction (RT-PCR) detection of prostate-specific antigen (PSA) mRNA in the blood of men with hormone-refractory prostate cancer (HRPC)...
  6. ncbi request reprint Finasteride and flutamide therapy in patients with advanced prostate cancer: response to subsequent castration and long-term follow-up
    William K Oh
    Lank Center for Genitourinary Oncology, Department of Medical Oncology, Dana Farber Cancer Institute and Harvard Medical School, Boston, Massachusetts 02115, USA
    Urology 62:99-104. 2003
    ..Standard androgen deprivation strategies for prostate cancer typically lead to castrate levels of testosterone. One alternative is the use of finasteride and flutamide...
  7. doi request reprint Interval to testosterone recovery after hormonal therapy for prostate cancer and risk of death
    Anthony V D'Amico
    Department of Radiation Oncology, Brigham and Women s Hospital and Dana Farber Cancer Institute, Boston, MA 02215, USA
    Int J Radiat Oncol Biol Phys 75:10-5. 2009
    ..To assess whether the risk of death is associated with the time to testosterone recovery (TTR) after radiotherapy (RT) and hormonal therapy (HT) for prostate cancer (PCa)...
  8. pmc Estrogen-dependent signaling in a molecularly distinct subclass of aggressive prostate cancer
    Sunita R Setlur
    Department of Pathology, Brigham and Women s Hospital, Boston, MA, USA
    J Natl Cancer Inst 100:815-25. 2008
    ....
  9. doi request reprint Evaluating the combined effect of comorbidity and prostate-specific antigen kinetics on the risk of death in men after prostate-specific antigen recurrence
    Jennifer Y Wo
    Harvard Radiation Oncology Program, Harvard Medical School, Boston, MA, USA
    J Clin Oncol 27:6000-5. 2009
    ....
  10. pmc Phase II study of sunitinib in men with advanced prostate cancer
    M Dror Michaelson
    Division of Hematology Oncology, Massachusetts General Hospital, Boston, MA 02114, USA
    Ann Oncol 20:913-20. 2009
    ..This study explored the efficacy and tolerability of sunitinib, an inhibitor of tyrosine kinase receptors, in men with castration-resistant prostate cancer (CRPC)...
  11. ncbi request reprint Prognostic significance of plasma vascular endothelial growth factor levels in patients with hormone-refractory prostate cancer treated on Cancer and Leukemia Group B 9480
    D J George
    Lank Center for Genitourinary Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts 02115, USA
    Clin Cancer Res 7:1932-6. 2001
    ..CONCLUSION: Although these data are exploratory and need to be confirmed in an independent data set, they suggest that VEGF may have clinical significance in patients with HRPC...
  12. ncbi request reprint Risk of prostate cancer recurrence in men treated with radiation alone or in conjunction with combined or less than combined androgen suppression therapy
    Anthony V D'Amico
    Department of Radiation, Brigham and Women s Hospital and Dana Farber Cancer Institute, Boston, MA 02215, USA
    J Clin Oncol 26:2979-83. 2008
    ..We determined the risk of recurrence in men enrolled on a randomized trial for prostate cancer who were treated with radiation therapy (RT) alone or in conjunction with combined or less than combined androgen suppression therapy (AST)...
  13. ncbi request reprint Complications after treatment with external-beam irradiation in early-stage prostate cancer patients: a prospective multiinstitutional outcomes study
    C J Beard
    Joint Center for Radiation Therapy, Boston, MA 02115, USA
    J Clin Oncol 15:223-9. 1997
    ..To use data from a prospective quality-of-life study to assess differences in disease-specific and general health-related quality-of-life changes after treatment with different external-beam irradiation techniques for prostate cancer...
  14. ncbi request reprint Utilizing predictions of early prostate-specific antigen failure to optimize patient selection for adjuvant systemic therapy trials
    A V D'Amico
    Department of Radiation Oncology, Brigham and Women s Hospital, Harvard Medical School, Boston, MA 02115, USA
    J Clin Oncol 18:3240-6. 2000
    ..This study was performed to estimate 2-year PSA failure rates on the basis of readily available clinical and pathologic factors to identify patients for whom effective adjuvant systemic therapy is needed...
  15. doi request reprint Response to docetaxel/carboplatin-based chemotherapy as first- and second-line therapy in patients with metastatic hormone-refractory prostate cancer
    Mari Nakabayashi
    Lank Center for Genitourinary Oncology, Department of Medical Oncology, Dana Farber Cancer Institute and Harvard Medical School, Boston, MA 02115, USA
    BJU Int 101:308-12. 2008
    ..To evaluate the efficacy of docetaxel/carboplatin (DC)-based chemotherapy as first- and second-line chemotherapy for patients with hormone-refractory prostate cancer (HRPC)...
  16. ncbi request reprint Chemotherapy for prostate cancer
    Timothy Gilligan
    Lank Center for Genitourinary Oncology, Dana Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts 02115, USA
    Urology 60:94-100; discussion 100. 2002
    ..Finally, the utility of chemotherapy is beginning to be explored in the context of earlier disease in the neoadjuvant, adjuvant, or serologically relapsing group of patients. Data from these studies are just beginning to be gathered...
  17. doi request reprint Inherited variation in the androgen pathway is associated with the efficacy of androgen-deprivation therapy in men with prostate cancer
    Robert W Ross
    Dana Farber Cancer Institute, Dana 710 C, 44 Binney St, Boston, MA 02115, USA
    J Clin Oncol 26:842-7. 2008
    ..Androgen-deprivation therapy (ADT) is the most common and effective systemic therapy for advanced prostate cancer. We hypothesized that germline genetic variation in the androgen axis would improve the efficacy of ADT...
  18. doi request reprint Androgen suppression and radiation vs radiation alone for prostate cancer: a randomized trial
    Anthony V D'Amico
    Department of Radiation Oncology, Brigham and Women s Hospital and Dana Farber Cancer Institute, Boston, Massachusetts 02115, USA
    JAMA 299:289-95. 2008
    ..Comorbidities may increase the negative effects of specific anticancer treatments such as androgen suppression therapy (AST)...
  19. ncbi request reprint Activity of the herbal combination, PC-SPES, in the treatment of patients with androgen-independent prostate cancer
    W K Oh
    Lank Center for Genitourinary Oncology, Department of Adult Oncology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, Massachusetts, USA
    Urology 57:122-6. 2001
    ..Additional testing is necessary to identify the active components of PC-SPES and its role in the treatment of patients with androgen-independent prostate cancer...
  20. ncbi request reprint Racial variation in prostate cancer incidence and in hormonal system markers among male health professionals
    E A Platz
    Department of Nutrition, Harvard School of Public Health, Boston, MA, USA
    J Natl Cancer Inst 92:2009-17. 2000
    ..Whether differences in the distribution of known or suspected risk factors among racial groups explain this variation is unknown...
  21. ncbi request reprint Vinorelbine and estramustine in androgen-independent metastatic prostate cancer: a phase II study
    M R Smith
    Massachusetts General Hospital, Boston, Massachusetts, USA
    Cancer 89:1824-8. 2000
    ..The aim of this study was to determine the safety and activity of vinorelbine in combination with estramustine in men with androgen-independent metastatic prostate cancer...
  22. ncbi request reprint Prognostic significance of baseline reverse transcriptase-PCR for prostate-specific antigen in men with hormone-refractory prostate cancer treated with chemotherapy
    Robert W Ross
    Dana Farber Cancer Institute, Harvard Medical School Boston, Massachusetts 02115, USA
    Clin Cancer Res 11:5195-8. 2005
    ....
  23. ncbi request reprint Neoadjuvant docetaxel before radical prostatectomy in patients with high-risk localized prostate cancer
    Phillip G Febbo
    Lank Center for Genitourinary Oncology, Department of Medical Oncology, Dana Farber Cancer Institute, Boston Massachusetts 02115, USA
    Clin Cancer Res 11:5233-40. 2005
    ..To determine the clinical, pathologic, and molecular effects of neoadjuvant docetaxel chemotherapy in high-risk localized prostate cancer...
  24. ncbi request reprint Response to low-dose ketoconazole and subsequent dose escalation to high-dose ketoconazole in patients with androgen-independent prostate cancer
    Mari Nakabayashi
    Lank Center for Genitourinary Oncology, Department of Medical Oncology, Dana Farber Cancer Institute and Harvard Medical School, Boston, Massachusetts 02115, USA
    Cancer 107:975-81. 2006
    ..To the authors' knowledge, relatively little is known regarding the efficacy of LDK in AIPC. The efficacy of LDK and of subsequent dose escalation from LDK to HDK was evaluated as secondary hormonal therapy in patients with AIPC...
  25. doi request reprint A phase II study of mifepristone (RU-486) in castration-resistant prostate cancer, with a correlative assessment of androgen-related hormones
    Mary Ellen Taplin
    Dana Farber Cancer Institute, Harvard Medical School, Boston, MA 02115, USA
    BJU Int 101:1084-9. 2008
    ..To evaluate mifepristone (RU-486) in patients with castration-resistant prostate cancer (CRPC), with a correlative assessment of serum androgens and androgen metabolites..
  26. ncbi request reprint Association between the Met326Ile polymorphism of the p85alpha regulatory subunit of phosphatidylinositol 3-kinase and prostate cancer risk: a prospective study
    Aimée E Paradis
    The Lank Center for Genitourinary Oncology, Department of Adult Oncology, Dana Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts 02115, USA
    Cancer Epidemiol Biomarkers Prev 12:172-3. 2003
  27. ncbi request reprint Activity of ketoconazole after taxane-based chemotherapy in castration-resistant prostate cancer
    Mari Nakabayashi
    Lank Center for Genitourinary Oncology, Department of Medical Oncology, Dana Farber Cancer Institute and Harvard Medical School, Boston, MA 02115, USA
    BJU Int 105:1392-6. 2010
    ....
  28. doi request reprint Causes of death in men undergoing androgen suppression therapy for newly diagnosed localized or recurrent prostate cancer
    Anthony V D'Amico
    Department of Radiation Oncology, Brigham and Women s Hospital and Dana Farber Cancer Institute, Boston, MA 02215, USA
    Cancer 113:3290-7. 2008
    ..The authors estimated and characterized mortality after androgen suppression therapy (AST) use in men with newly diagnosed localized and recurrent prostate cancer...
  29. ncbi request reprint Hydrocortisone with or without mitoxantrone in men with hormone-refractory prostate cancer: results of the cancer and leukemia group B 9182 study
    P W Kantoff
    Lank Center for Genitourinary Oncology and Breast Oncology Center, Department of Adult Oncology, Dana Farber Cancer Institute, Harvard Medical School, Boston, MA 02115 6084, USA
    J Clin Oncol 17:2506-13. 1999
    ..The purpose of this study was to demonstrate an advantage of mitoxantrone and hydrocortisone (M+H) over hydrocortisone alone with respect to survival duration...
  30. ncbi request reprint Neoadjuvant docetaxel followed by radical prostatectomy in patients with high-risk localized prostate cancer: a preliminary report
    W K Oh
    Lank Center for Genitourinary Oncology, Department of Adult Oncology, Dana-Farber Cancer Institute, Boston, MA 02115, USA
    Semin Oncol 28:40-4. 2001
    ..The primary endpoint of the trial is measurement of pathologic complete response rate, for which data are not yet available. Recruitment to the trial is ongoing...
  31. ncbi request reprint Patient-reported symptoms after primary therapy for early prostate cancer: results of a prospective cohort study
    J A Talcott
    Dana Farber Cancer Institute, Brigham and Women s Hospital, Boston, MA, USA
    J Clin Oncol 16:275-83. 1998
    ..To assess complications of therapy for early (nonmetastatic) prostate cancer...
  32. ncbi request reprint Activity of dutasteride plus ketoconazole in castration-refractory prostate cancer after progression on ketoconazole alone
    Oliver Sartor
    Dana Farber Cancer Institute, Boston, MA, USA
    Clin Genitourin Cancer 7:E90-2. 2009
    ..We hypothesized that SRDA5 inhibition in combination with ketoconazole would mitigate progression after treatment with ketoconazole alone...
  33. ncbi request reprint Radical prostatectomy lowers plasma vascular endothelial growth factor levels in patients with prostate cancer
    Daniel J George
    Lank Center for Genitourinary Oncology, Division of Solid Tumor Oncology, Department of Medical Oncology, Dana Farber Cancer Institute, Boston, Massachusetts, USA
    Urology 63:327-32. 2004
    ..To measure the change in plasma vascular endothelial growth factor (VEGF) levels after radical prostatectomy (RP) and to examine the association of pre-RP VEGF levels with known prognostic factors...
  34. ncbi request reprint Finasteride and bicalutamide as primary hormonal therapy in patients with advanced adenocarcinoma of the prostate
    M H Tay
    Lank Center for Genitourinary Oncology, Division of Solid Tumor Oncology, Department of Medical Oncology, Dana Farber Cancer Institute, Boston, MA 02115, USA
    Ann Oncol 15:974-8. 2004
    ..Effective, less toxic therapies are needed. This study examined whether the addition of finasteride to high-dose bicalutamide enhanced disease control, as measured by additional decreases in serum prostate-specific antigen (PSA)...
  35. ncbi request reprint Treatment of locally advanced prostate cancer: is chemotherapy the next step?
    W K Oh
    Lank Center for Genitourinary Oncology, Department of Adult Oncology, Dana Farber Cancer Institute and Harvard Medical School, Boston, MA, USA
    J Clin Oncol 17:3664-75. 1999
    ..The purpose of this review is to define the current knowledge in managing locally advanced prostate cancer and to propose new treatment approaches based on current knowledge...
  36. ncbi request reprint The relationship between a polymorphism in CYP17 with plasma hormone levels and prostate cancer
    C A Haiman
    Department of Epidemiology, Harvard School of Public Health, Boston, MA 02115, USA
    Cancer Epidemiol Biomarkers Prev 10:743-8. 2001
    ..These results suggest that CYP17 genotype may possibly confer a small increased susceptibility to prostate cancer but is not a strong predictor of endogenous steroid hormone levels in men...
  37. ncbi request reprint The androgen receptor CAG repeat polymorphism and risk of breast cancer in the Nurses' Health Study
    Christopher A Haiman
    Department of Epidemiology, Harvard Center for Cancer Prevention, Harvard School of Public Health, Boston, Massachusetts 02115, USA
    Cancer Res 62:1045-9. 2002
    ..However, these data suggest that longer AR [CAG](n) repeat alleles may increase breast cancer risk among women with a first-degree family history of breast cancer...
  38. ncbi request reprint Prospective, multicenter, randomized phase II trial of the herbal supplement, PC-SPES, and diethylstilbestrol in patients with androgen-independent prostate cancer
    William K Oh
    Lank Center for Genitourinary Oncology, Dana Farber Cancer Institute, Boston, MA, USA
    J Clin Oncol 22:3705-12. 2004
    ..To evaluate the herbal combination, PC-SPES, and diethylstilbestrol (DES) in patients with androgen independent prostate cancer (AIPC)...
  39. ncbi request reprint Neoadjuvant doxil chemotherapy prior to androgen ablation plus radiotherapy for high-risk localized prostate cancer: feasibility and toxicity
    William K Oh
    Lank Center for Genitourinary Oncology, Department of Adult Oncology, Dana Farber Cancer Institute, Boston, Massachusetts 02115, USA
    Am J Clin Oncol 26:312-6. 2003
    ..Neoadjuvant liposomal doxorubicin demonstrates no apparent activity and significant toxicity. New strategies are needed to improve outcomes in high-risk prostate cancer...
  40. ncbi request reprint Decreased alpha-methylacyl CoA racemase expression in localized prostate cancer is associated with an increased rate of biochemical recurrence and cancer-specific death
    Mark A Rubin
    Department of Pathology Amory 3 195, Brigham and Women s Hospital, Harvard Medical School, 75 Francis Street, Boston, Massachusetts 02115, USA
    Cancer Epidemiol Biomarkers Prev 14:1424-32. 2005
    ..This is the first study to show that AMACR expression is significantly associated with prostate cancer progression and suggests that not all surrogate end points may be optimal to define biomarkers of aggressive prostate cancer...
  41. pmc Inherited variations in AR, ESR1, and ESR2 genes are not associated with prostate cancer aggressiveness or with efficacy of androgen deprivation therapy
    Tong Sun
    Department of Medical Oncology, Dana Farber Cancer Institute and Harvard Medical School, Boston, Massachusetts 02115, USA
    Cancer Epidemiol Biomarkers Prev 19:1871-8. 2010
    ..Sex steroid hormone receptors mediate essential processes in normal prostate growth and contribute to prostate cancer development...
  42. pmc Evaluation of the 8q24 prostate cancer risk locus and MYC expression
    Mark M Pomerantz
    Department of Medical Oncology, Dana Farber Cancer Institute, Boston, MA 02115, USA
    Cancer Res 69:5568-74. 2009
    ..These data will help to direct the future study of this risk locus...
  43. pmc Multicenter phase II study of trabectedin in patients with metastatic castration-resistant prostate cancer
    M D Michaelson
    Massachusetts General Hospital Cancer Center, Boston, MA 02114, USA
    Ann Oncol 23:1234-40. 2012
    ..This multicenter phase II trial evaluated the efficacy and safety of trabectedin in metastatic castration-resistant prostate cancer (CRPC)...
  44. ncbi request reprint Biochemical outcome following external beam radiation therapy with or without androgen suppression therapy for clinically localized prostate cancer
    A V D'Amico
    Brigham and Women s Hospital and Dana Farber Cancer Institute, Department of Radiation Therapy, Harvard Medical School, 75 Francis St, L 2 Level, Boston, MA 02115, USA
    JAMA 284:1280-3. 2000
    ....
  45. ncbi request reprint Pamidronate to prevent bone loss during androgen-deprivation therapy for prostate cancer
    M R Smith
    Massachusetts General Hospital, Boston 02114, USA
    N Engl J Med 345:948-55. 2001
    ..We conducted a controlled study of the prevention of osteoporosis in men undergoing treatment with a gonadotropin-releasing hormone agonist...
  46. ncbi request reprint Phase I/II study of vaccination with electrofused allogeneic dendritic cells/autologous tumor-derived cells in patients with stage IV renal cell carcinoma
    David E Avigan
    Beth Israel Deaconess Medical Center and Dana Farber Cancer Institute, Harvard Medical School, Boston, MA 02215, USA
    J Immunother 30:749-61. 2007
    ..Vaccination of patients with RCC with allogeneic DC/tumor fusions was feasible, well tolerated, and resulted in immunologic and clinical responses in a subset of patients...
  47. ncbi request reprint Prostate-specific antigen screening for prostate cancer: a decision-analytical perspective
    Julia H Hayes
    Diana Farber Cancer Institute, Center for Genitourinary Oncology, Massachusetts General Hospital, Boston, MA, USA
    BJU Int 100:486-8. 2007
  48. pmc A large prospective study of SEP15 genetic variation, interaction with plasma selenium levels, and prostate cancer risk and survival
    Kathryn L Penney
    Department of Epidemiology, Harvard School of Public Health, Boston, MA 02115, USA
    Cancer Prev Res (Phila) 3:604-10. 2010
    ..Additionally, the association of selenium with PCa mortality was modified by a variant, suggesting the possibility that some men with PCa may benefit more from selenium than others, depending on their genotype...
  49. doi request reprint Nine-gene molecular signature is not associated with prostate cancer death in a watchful waiting cohort
    Lorelei A Mucci
    Channing Laboratory, Department of Medicine, Brigham and Women s Hospital and Harvard Medical School, 181 Longwood Avenue, Boston, MA 02115, USA
    Cancer Epidemiol Biomarkers Prev 17:249-51. 2008
    ..We quantified protein expression of the nine genes in tumors to classify progression risk. Accounting for clinical prognostic factors, the nine-gene model did not provide discrimination to predict lethal and indolent prostate cancer...
  50. pmc Randomized controlled trial of annual zoledronic acid to prevent gonadotropin-releasing hormone agonist-induced bone loss in men with prostate cancer
    M Dror Michaelson
    Division of Hematology and Oncology and Endocrine Unit, Massachusetts General Hospital, Boston, MA 02114, USA
    J Clin Oncol 25:1038-42. 2007
    ..Annual zoledronic acid increases BMD in postmenopausal women, but its efficacy in hypogonadal men is not known...
  51. ncbi request reprint Hormone-refractory prostate cancer: choosing the appropriate treatment option
    Robert W Ross
    Harvard Medical School, Lank Center for Genitourinary Oncology, Dana Farber Cancer Institute, Boston, Massachusetts, USA
    Oncology (Williston Park) 21:185-93; discussion 194, 199-200. 2007
    ..Several promising novel therapies are in late-stage testing and will hopefully provide more treatment options for these patients...
  52. ncbi request reprint Influence of androgen suppression therapy for prostate cancer on the frequency and timing of fatal myocardial infarctions
    Anthony V D'Amico
    Departments of Radiation Oncology and Medicine, Cardiovascular Division, Brigham and Women s Hospital and Lank Center for Genitourinary Oncology, Dana Farber Cancer Institute, Boston, MA 02215, USA
    J Clin Oncol 25:2420-5. 2007
    ..We evaluated whether the timing of fatal myocardial infarction (MI) was influenced by the administration of androgen suppression therapy (AST)...
  53. pmc Immunohistochemical expression of BRCA1 and lethal prostate cancer
    Michelangelo Fiorentino
    Department of Pathology, Dana Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts 02115, USA
    Cancer Res 70:3136-9. 2010
    ..6; 95% confidence interval, 2.4-8.7). These findings strengthen the hypothesis that BRCA1 plays a role in cell cycle control and show that BRCA1 is a marker of clinical prostate cancer prognosis. Cancer Res; 70(8); 3136-9. (c)2010 AACR...
  54. doi request reprint Efficacy of androgen deprivation therapy (ADT) in patients with advanced prostate cancer: association between Gleason score, prostate-specific antigen level, and prior ADT exposure with duration of ADT effect
    Robert W Ross
    Harvard Medical School, Dana Farber Cancer Institute, Boston, Massachusetts 02115, USA
    Cancer 112:1247-53. 2008
    ..The purpose of this study was to compare predictive factors for the efficacy of androgen deprivation therapy (ADT) in men with hormone-sensitive prostate cancer (HSPC) either with (M+) or without (M-) metastases...
  55. pmc Polymorphism in endostatin, an angiogenesis inhibitor, and prostate cancer risk and survival: A prospective study
    Lorelei A Mucci
    Department of Medicine, Brigham and Women s Hospital and Harvard Medical School, Boston, MA 02115, USA
    Int J Cancer 125:1143-6. 2009
    ..However, our data indicate that prostate cancer cases who carry the variant N allele are more likely to be overweight, and may be more susceptible to the angiogenic influences of obesity in prostate cancer pathogenesis...
  56. doi request reprint Survival following radiation and androgen suppression therapy for prostate cancer in healthy older men: implications for screening recommendations
    Paul L Nguyen
    Harvard Radiation Oncology Program, Department of Radiation Oncology, Brigham and Women s Hospital, Boston, MA 02115, USA
    Int J Radiat Oncol Biol Phys 76:337-41. 2010
    ..The U.S. Preventive Services Task Force has recommended against screening men over 75 for prostate cancer. We examined whether older healthy men could benefit from aggressive prostate cancer treatment...
  57. pmc Androgen receptor regulates a distinct transcription program in androgen-independent prostate cancer
    Qianben Wang
    Department of Medical Oncology, Dana Farber Cancer Institute and Harvard Medical School, Boston, MA 02115, USA
    Cell 138:245-56. 2009
    ..Thus, the role of AR in androgen-independent cancer cells is not to direct the androgen-dependent gene expression program without androgen, but rather to execute a distinct program resulting in androgen-independent growth...
  58. pmc Time to prostate-specific antigen nadir independently predicts overall survival in patients who have metastatic hormone-sensitive prostate cancer treated with androgen-deprivation therapy
    Toni K Choueiri
    Dana Farber Cancer Institute Brigham and Women s Hospital and Harvard Medical School, Boston, Massachusetts, USA
    Cancer 115:981-7. 2009
    ....
  59. pmc Testing a multigene signature of prostate cancer death in the Swedish Watchful Waiting Cohort
    Lorelei A Mucci
    Channing Laboratory, Brigham and Women s Hospital, Boston, MA 02115, USA
    Cancer Epidemiol Biomarkers Prev 17:1682-8. 2008
    ..78) than the clinical model alone (area under the curve = 0.71; P = 0.04). Molecular tumor markers can add to clinical variables to help distinguish lethal and indolent prostate cancer and hold promise to guide treatment decisions...
  60. pmc Active surveillance compared with initial treatment for men with low-risk prostate cancer: a decision analysis
    Julia H Hayes
    Lank Center for Genitourinary Oncology, Dana Farber Cancer Institute, Boston, MA 02115, USA
    JAMA 304:2373-80. 2010
    ..Treatment of these cancers is associated with substantial morbidity. Active surveillance is an alternative to initial treatment, but long-term outcomes and effect on quality of life have not been well characterized...
  61. doi request reprint Radiation with or without 6 months of androgen suppression therapy in intermediate- and high-risk clinically localized prostate cancer: a postrandomization analysis by risk group
    Paul L Nguyen
    Department of Radiation Oncology, Dana Farber Cancer Institute and Brigham and Women s Hospital, Boston, Massachusetts 02115, USA
    Int J Radiat Oncol Biol Phys 77:1046-52. 2010
    ..RT alone in men with unfavorable risk localized prostate cancer (PCa), but it is unknown if this benefit applies to all risk subgroups and, in particular, the intermediate-risk group...
  62. doi request reprint Comorbidity, body mass index, and age and the risk of nonprostate-cancer-specific mortality after a postradiation prostate-specific antigen recurrence
    Paul L Nguyen
    Department of Radiation Oncology, Dana Farber Cancer Institute and Brigham and Women s Hospital, Boston, Massachusetts 02115, USA
    Cancer 116:610-5. 2010
    ..Therefore, our ability to determine who would benefit from salvage hormonotherapy (HT) would be enhanced if an individual's risk of nonprostate-cancer-specific mortality were known...
  63. ncbi request reprint Development of an integrated prostate cancer research information system
    William K Oh
    Lank Center for Genitourinary Oncology, Dana Farber Cancer Institute, Boston, MA 02115, USA
    Clin Genitourin Cancer 5:61-6. 2006
    ..In this article, we describe the design and implementation of a comprehensive prostate cancer database developed to collect, store, and access clinical, treatment, and outcomes data for research and clinical care...
  64. ncbi request reprint Celecoxib versus placebo for men with prostate cancer and a rising serum prostate-specific antigen after radical prostatectomy and/or radiation therapy
    Matthew R Smith
    Massachusetts General Hospital, Cancer Center, Boston MA 02114, USA
    J Clin Oncol 24:2723-8. 2006
    ..To assess the biologic activity of celecoxib, a selective cyclooxygenase-2 inhibitor, in men with recurrent prostate cancer using change in prostate-specific antigen (PSA) doubling time (PSADT) as the primary outcome variable...
  65. ncbi request reprint Response to second-line chemotherapy in patients with hormone refractory prostate cancer receiving two sequences of mitoxantrone and taxanes
    William K Oh
    Lank Center for Genitourinary Oncology, Dana Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts 02115, USA
    Urology 67:1235-40. 2006
    ..Clinical trials have demonstrated a survival benefit with docetaxel chemotherapy, but limited data exist regarding the activity of second-line chemotherapy...
  66. ncbi request reprint Rapid rise of serum prostate specific antigen levels after discontinuation of the herbal therapy PC-SPES in patients with advanced prostate carcinoma: report of four cases
    William K Oh
    The Lank Center for Genitourinary Oncology, Department of Adult Oncology, Dana Farber Cancer Institute, Boston, Massachusetts 02115, USA
    Cancer 94:686-9. 2002
    ..The objective of the current report is to describe the effects of discontinuing PC-SPES treatment in four patients with androgen-independent prostate carcinoma...
  67. ncbi request reprint A phase II trial of interferon-alpha and toremifene in advanced renal cell cancer patients
    William K Oh
    Lank Center for Genitourinary Oncology, Department of Adult Oncology, Dana Farber Cancer Institute and Harvard Medical School, 44 Binney Street, Boston, MA 02115, USA
    Cancer Invest 20:186-91. 2002
    ..We conclude that the combination of interferon-alpha plus toremifene demonstrates no significant activity in advanced renal cell carcinoma...
  68. ncbi request reprint Absence of a correlation of androgen receptor gene CAG repeat length and prostate cancer risk in an African-American population
    Timothy Gilligan
    Department of Medical Oncology, Dana Farber Cancer Institute, Boston, MA 02115, USA
    Clin Prostate Cancer 3:98-103. 2004
    ..This study confirms earlier reports that black men have shorter CAG repeat lengths than reported white and Asian populations. We did not find an increased risk of prostate cancer among black men with fewer CAG repeats...
  69. ncbi request reprint Rosiglitazone versus placebo for men with prostate carcinoma and a rising serum prostate-specific antigen level after radical prostatectomy and/or radiation therapy
    Matthew R Smith
    Division of Hematology and Medical Oncology, Massachusetts General Hospital, Boston 02114, USA
    Cancer 101:1569-74. 2004
    ....
  70. ncbi request reprint Racial differences in screening for prostate cancer in the elderly
    Timothy Gilligan
    Department of Medical Oncology, Dana Farber Cancer Institute, Boston, MA 02115, USA
    Arch Intern Med 164:1858-64. 2004
    ..Low screening rates among black men may contribute to these disparities, but there are few data on racial differences in prostate cancer screening...
  71. ncbi request reprint 6-month androgen suppression plus radiation therapy vs radiation therapy alone for patients with clinically localized prostate cancer: a randomized controlled trial
    Anthony V D'Amico
    Department of Radiation Oncology, Brigham and Women s Hospital and Dana Farber Cancer Institute, Boston, Mass 02215, USA
    JAMA 292:821-7. 2004
    ....
  72. ncbi request reprint Plasma levels of heat shock protein 70 in patients with prostate cancer: a potential biomarker for prostate cancer
    Miyako Abe
    The Lank Center for Genitourinary Oncology, Dana Farber Cancer Institute, Boston, MA 02115, USA
    Clin Prostate Cancer 3:49-53. 2004
    ..It is possible that when used in conjunction with PSA it might prove useful in identifying patients with early-stage prostate cancer who might otherwise be missed by PSA screening alone...
  73. ncbi request reprint Peroxisome proliferator-activated receptor gamma (PPargamma) as a novel target for prostate cancer
    Matthew R Smith
    Massachusetts General Hospital, Boston 02114, USA
    Invest New Drugs 20:195-200. 2002
    ..Here we review the evidence that PPARgamma contributes to prostate carcinogenesis and the potential for PPARgamma as a novel therapeutic target for prostate cancer...
  74. ncbi request reprint Time course and predictors of symptoms after primary prostate cancer therapy
    James A Talcott
    Center for Outcomes Research, MGH Cancer Center, Massachusetts General Hospital, Boston, 02114 2696, USA
    J Clin Oncol 21:3979-86. 2003
    ..We characterized the time course of treatment complications while adjusting for potentially confounding pretreatment factors hindering other observational studies...
  75. ncbi request reprint Differentiating agents and the treatment of prostate cancer: Vitamin D3 and peroxisome proliferator-activated receptor gamma ligands
    Stacey B Leibowitz
    Department of Medical Oncology, Dana Farber Cancer Institute and Harvard Medical School, Boston, MA 02115, USA
    Semin Oncol 30:698-708. 2003
    ..The proposed mechanisms of action of these agents and potential future therapeutic roles for these drugs are discussed as well...
  76. ncbi request reprint Physician attitudes toward cytotoxic chemotherapy use in patients with advanced prostate carcinoma
    William K Oh
    Lank Center for Genitourinary Oncology, Department of Adult Oncology, Dana Farber Harvard Cancer Center, Dana Farber Cancer Institute, Boston, Massachusetts 02115, USA
    Cancer 97:2171-9. 2003
    ..This is important as randomized trials using chemotherapy are proposed. The authors used a questionnaire to investigate the attitudes of physicians in the New England area who care for patients with advanced prostate carcinoma...
  77. ncbi request reprint A phase I study of estramustine, weekly docetaxel, and carboplatin chemotherapy in patients with hormone-refractory prostate cancer
    William K Oh
    Lank Center for Genitourinary Oncology, Department of Medical Oncology, Dana Farber Cancer Institute, Massachusetts 02115, USA
    Clin Cancer Res 11:284-9. 2005
    ..To define the maximal tolerated dose, safety, and efficacy of docetaxel, carboplatin, and estramustine in patients with hormone-refractory prostate cancer (HRPC)...
  78. ncbi request reprint Selective aromatase inhibition for patients with androgen-independent prostate carcinoma
    Matthew R Smith
    Department of Hematology Oncology, Massachusetts General Hospital, Boston 02114, USA
    Cancer 95:1864-8. 2002
    ..The authors conducted a Phase II clinical study of letrozole to determine the safety and efficacy of a potent and selective third-generation aromatase inhibitor in men with androgen-independent prostate carcinoma...
  79. ncbi request reprint Predictors of prostate cancer tissue acquisition by an undirected core bone marrow biopsy in metastatic castration-resistant prostate cancer--a Cancer and Leukemia Group B study
    Robert W Ross
    Dana Farber Cancer Institute, Boston, Massachusetts 02115, USA
    Clin Cancer Res 11:8109-13. 2005
    ..We assessed factors predicting a successful tumor harvest from bone marrow biopsies (BMBx) in castration-resistant metastatic prostate cancer patients...
  80. ncbi request reprint Manganese superoxide dismutase polymorphism, prediagnostic antioxidant status, and risk of clinical significant prostate cancer
    Haojie Li
    Channing Laboratory, Department of Medicine Brigham and Women s Hospital and Harvard Medical School, Boston, MA 02115, USA
    Cancer Res 65:2498-504. 2005
    ..Both endogenous and exogenous antioxidants play an important and interdependent role in preventing clinically significant prostate cancer...
  81. ncbi request reprint Initial decline in hemoglobin during neoadjuvant hormonal therapy predicts for early prostate specific antigen failure following radiation and hormonal therapy for patients with intermediate and high-risk prostate cancer
    Anthony V D'Amico
    Department of Radiation Oncology, Brigham and Women s Hospital, Boston, Massachusetts 02115, USA
    Cancer 95:275-80. 2002
    ....
  82. ncbi request reprint Prediagnostic plasma vascular endothelial growth factor levels and risk of prostate cancer
    Haojie Li
    Channing Laboratory, Department of Medicine, Brigham and Women s Hospital and Harvard Medical School, Room 452, 181 Longwood Avenue, Boston, Massachusetts 02115, USA
    Cancer Epidemiol Biomarkers Prev 14:1557-61. 2005
    ..Our results indicate that prediagnostic circulating VEGF levels are not associated with prostate cancer development and have limited value in predicting future risk of prostate cancer...
  83. ncbi request reprint CAG repeat within the androgen receptor gene and incidence of surgery for benign prostatic hyperplasia in U.S. physicians
    E Giovannucci
    Department of Medicine, Brigham and Women s Hospital and Harvard Medical School, Boston, Massachusetts, USA
    Prostate 39:130-4. 1999
    ..Because benign prostatic hyperplasia (BPH) is an androgen-dependent condition, we examined the hypothesis that a shorter AR gene CAG repeat length increases the risk of developing of BPH...
  84. ncbi request reprint Chemotherapy for metastatic bladder cancer
    P W Kantoff
    Department of Medicine, Dana Farber Cancer Institute, Boston, Massachusetts
    Hematol Oncol Clin North Am 6:195-203. 1992
    ..The available data would strongly suggest that therapy needs to be improved, and therefore current regimens should not be considered the standards of care as much as the standards of comparison for improved future treatments...
  85. ncbi request reprint Low bone mineral density in hormone-naïve men with prostate carcinoma
    M R Smith
    Hematology Oncology Division, Massachusetts General Hospital, Boston, Massachusetts 02114, USA
    Cancer 91:2238-45. 2001
    ..The objective of this study was to determine the prevalence of low bone mineral density in men with prostate carcinoma and no history of androgen-deprivation therapy...
  86. ncbi request reprint TMPRSS2:ERG gene fusion associated with lethal prostate cancer in a watchful waiting cohort
    F Demichelis
    Department of Pathology, Brigham and Women s Hospital, Boston, MA 02115 6110, USA
    Oncogene 26:4596-9. 2007
    ..005). These data suggest that TMPRSS2:ERG fusion prostate cancers may have a more aggressive phenotype, possibly mediated through increased ERG expression...
  87. pmc The CAG repeat within the androgen receptor gene and its relationship to prostate cancer
    E Giovannucci
    Channing Laboratory, Brigham and Women s Hospital and Harvard Medical School, Boston, MA 02115, USA
    Proc Natl Acad Sci U S A 94:3320-3. 1997
    ..The clinical implications of these results should be evaluated further...
  88. pmc MiR-221 promotes the development of androgen independence in prostate cancer cells via downregulation of HECTD2 and RAB1A
    T Sun
    Department of Medical Oncology, Dana Farber Cancer Institute, Harvard Medical School, Boston, MA, USA
    Oncogene 33:2790-800. 2014
    ..We hypothesize that a major biological consequence of upregulation of miR-221 is reprogramming of AR signaling, which in turn may mediate the transition to the CRPC phenotype. ..
  89. ncbi request reprint No association between the I105V polymorphism of the glutathione S-transferase P1 gene (GSTP1) and prostate cancer risk: a prospective study
    T F Shepard
    The Lank Center for Genitourinary Oncology, Department of Adult Oncology, Dana Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts 02115, USA
    Cancer Epidemiol Biomarkers Prev 9:1267-8. 2000
  90. ncbi request reprint Two differentially expressed genes in normal human prostate tissue and in carcinoma
    F L Wang
    Division of Cell Growth and Regulation, Dana Farber Cancer Institute, Harvard Medical School, Boston, Massauchesetts 02115, USA
    Cancer Res 56:3634-7. 1996
    ..The expression pattern of COSVIc may be a useful marker for studying the alteration of energy metabolism in cancer cells and for the diagnosis of prostate cancer...
  91. doi request reprint Pain predicts overall survival in men with metastatic castration-refractory prostate cancer
    Susan Halabi
    Department of Biostatistics and Bioinformatics, Duke University, and Cancer and Leukemia Group B Statistical Center, Durham, NC, USA
    J Clin Oncol 26:2544-9. 2008
    ..The objective of this study was to determine whether men with CRPC who had higher pain interference scores at baseline had worse clinical outcomes compared with men who had lower pain scores...
  92. ncbi request reprint Overview consensus statement. Newer approaches to androgen deprivation therapy in prostate cancer
    Peter R Carroll
    Department of Urology, University of California School of Medicine, San Francisco, San Francisco, California, USA
    Urology 60:1-6. 2002
  93. ncbi request reprint Importance of serum hemoglobin in hormone refractory prostate cancer
    Robin T Vollmer
    Laboratory Medicine, Veterans Affairs Medical Center and Department of Pathology, Duke University Medical Center, Durham, North Carolina 27705, USA
    Clin Cancer Res 8:1049-53. 2002
    ..If dynamic changes in hemoglobin after treatment provide additive prognostic information to dynamic changes in PSA, then we should consider and test ways to incorporate serum hemoglobin into measures of response in HRPC...
  94. ncbi request reprint Changes in body composition during androgen deprivation therapy for prostate cancer
    Matthew R Smith
    Massachusetts General Hospital, Boston, Massachusetts 02114, USA
    J Clin Endocrinol Metab 87:599-603. 2002
    ..Increased fatness resulted primarily from accumulation of sc rather than intraabdominal adipose tissue...
  95. ncbi request reprint Phase II study of low dose and high dose conjugated estrogen for androgen independent prostate cancer
    Mark Pomerantz
    Lank Center for Genitourinary Oncology, Dana Farber Cancer Institute, Harvard Medical School, 44 Binney Street, Boston, MA 02115, USA
    J Urol 177:2146-50. 2007
    ..We tested 2 doses of the conjugated estrogen Premarin(R) in patients with androgen independent prostate cancer to determine the efficacy and safety of this widely available medication...
  96. ncbi request reprint Prognostic model for predicting survival in men with hormone-refractory metastatic prostate cancer
    Susan Halabi
    Department of Biostatistics and Bioinformatics and CALGB Statistical Center, Duke University Medical Center, Durham, NC 27710, USA
    J Clin Oncol 21:1232-7. 2003
    ..To develop and validate a model that can be used to predict the overall survival probability among metastatic hormone-refractory prostate cancer patients (HRPC)...
  97. ncbi request reprint Efficacy of nilutamide as secondary hormonal therapy in androgen-independent prostate cancer
    Mari Nakabayashi
    Lank Center for Genitourinary Oncology, Department of Medical Oncology, Dana Haber Cancer Institute, Harvard Medical School, Boston, MA 02115, USA
    BJU Int 96:783-6. 2005
    ....
  98. ncbi request reprint Prognostic significance of plasma chromogranin a levels in patients with hormone-refractory prostate cancer treated in Cancer and Leukemia Group B 9480 study
    Mary Ellen Taplin
    Lank Center for Genitourinary Oncology, Dana Farber Cancer Institute, Boston, Massachusetts 02115, USA
    Urology 66:386-91. 2005
    ..Plasma CgA levels in patients with prostate cancer may reflect the extent of the tumor neuroendocrine phenotype...
  99. ncbi request reprint Prostate cancer risk and ESR1 TA, ESR2 CA repeat polymorphisms
    Matthew H McIntyre
    Channing Laboratory, Department of Medicine, Brigham and Women s Hospital and Harvard Medical School, 181 Longwood Avenue, Boston, MA 02115, USA
    Cancer Epidemiol Biomarkers Prev 16:2233-6. 2007
    ..Experimental evidence has suggested that estrogen receptor alpha (coded by the gene ESR1) might increase prostate cancer risk, whereas estrogen receptor beta (coded by the gene ESR2) might reduce prostate cancer risk...
  100. ncbi request reprint Sex steroid hormones and the androgen receptor gene CAG repeat and subsequent risk of prostate cancer in the prostate-specific antigen era
    Elizabeth A Platz
    Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health, Room E6138, 615 North Wolfe Street, Baltimore, MD 21205, USA
    Cancer Epidemiol Biomarkers Prev 14:1262-9. 2005
    ..We investigated plasma levels of sex steroid hormones and length of the androgen receptor gene CAG repeat in relation to incident prostate cancer diagnosed in the prostate-specific antigen (PSA) era...
  101. ncbi request reprint The prognostic significance of plasma interleukin-6 levels in patients with metastatic hormone-refractory prostate cancer: results from cancer and leukemia group B 9480
    Daniel J George
    Divisions of Urology and Medical Oncology, Cancer and Leukemia Group B Statistical Center, Duke University Medical Center, Durham, NC 2771, USA
    Clin Cancer Res 11:1815-20. 2005
    ..In order to evaluate its prognostic significance in metastatic HRCaP patients, we measured IL-6 in plasma collected at baseline from patients in a large cooperative group study [Cancer and Leukemia Group B 9480 (CALGB 9480)]...